The Vaccine Billionaire That Bet on Cancer

The Quiet Pharma Giant Building Its Next Act

GlaxoSmithKline Pharmaceuticals is not Infosys. It doesn’t flash growth numbers quarterly. It’s not Bharti Airtel either — it doesn’t move markets with tariff announcements. GSK is the kind of company that sits in your portfolio, pays dividend quietly, and every 18 months tells you they’ve diversified into a completely different category you weren’t paying attention to.

They’re the number-one vaccine player in India’s self-pay segment. They own the anti-infectives market. They’re number three by value in the entire Indian pharma industry. 75% promoter-held by the global GSK plc. Four manufacturing plants. Eight thousand employees. 46.9% ROE. 63.2% ROCE. Seventy-five percent dividend payout. The kind of numbers that make PE analysts cry happy tears.

But Q3 FY26 was different. For the first time, GSK India broke ₹1,000 crore in quarterly revenue. EBITDA margins touched 35.9%, highest on record. And the concall in February 2026 revealed that management is not just running a cash-generation machine — they’re building an oncology platform that could reshape the company’s growth trajectory over the next five years. Zejula and Jemperli are now in market. Forty endometrial cancer patients per month in December 2025. The addressable market just expanded six-fold thanks to a RUBY-1 approval. The old guard is evolving.

Let’s break down what GSK just pulled off, what it means, and whether a 42x P/E multiple on pharma legacy is bravery or arrogance.

Vaccines + Pills + Injectables + Now, Cancer Drugs. Basically Everything.

GSK India operates like a pharma supermarket. You walk in with any ailment — cold, cough, acne, antibiotics, vaccines, or cancer — and there’s a GSK product in aisle five. The company is split into three broad buckets:

Pharmaceuticals (76% of revenues): Essentially General Medicines. Augmentin is number one in the IPM. T-Bact dominates dermatology. Ceftum is the antibiotic choice. Calpol for fever. Vitamins. Pain management. Anti-infectives leadership. The kind of products your mom has stocked in her medicine cabinet since 1987. Growing at single digits, stable margins, mature market dynamics.

Vaccines (24% of FY21 revenues, now growing faster): This is the crown jewel. Pediatric vaccines (Boostrix, Varilrix, Havrix). Adult vaccines. And Shingrix — the herpes zoster vaccine that management is positioning as the next growth pillar. ~100,000 doses sold in CY2025. ₹70–75 crore annual sales from Shingrix alone. Management says it’s “touching 9,000–10,000 patients every month” and scaling.

Specialty (Growing from near-zero): Respiratory specialty (Trelegy Ellipta, Nucala). And now oncology. Zejula for ovarian cancer. Jemperli (dostarlimab) for endometrial cancer. Management closed Q3 FY26 with ~250 patients on these two drugs combined. The endometrial cancer addressable market just jumped from 800 to 6,000–7,000 eligible patients post-RUBY-1 approval. Management talks about a “bi-directional nature of Shingles prevention and CVMD (cardiovascular-metabolic disease) space.” Translation: they’re thinking in interconnected ecosystems, not silos.

Manufacturing: five plants (Nabha, Sonepat, Rajahmundry, two in Nashik). 98% of products sold in India are made locally. Global parent is GSK plc — world’s sixth-largest pharma company. That means R&D muscle, global regulatory experience, and the ability to run local trials as part of global studies.

Q3 FY26: The Breakout Quarter

Result type: Quarterly Results (Dec 2025)  |  Q3 EPS: ₹17.45  |  Annualised EPS (Q3×4): ₹69.8  |  TTM EPS: ₹60.27

Is ₹2,517 Fair, or Are We Pricing in the Fairy Tale?